Karyopharm Therapeutics (KPTI) Tops Q4 EPS by 1c ; Offers Guidance

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q4 EPS of ($0.24), $0.01 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $30.54 million versus the consensus estimate of $38.2 million.

GUIDANCE:

Karyopharm Therapeutics sees FY2025 revenue of $140-155 million, versus the consensus of $165.5 million.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Apollo Global Management (APO) call put ratio 1 call to 6.8 puts a focus on a spreader of 9K contracts January 95 and 135 puts
• IBM (IBM) call put ratio 9.7 calls to 1 put with a focus on August and September 285 calls
• Cerebras Systems (CBRS) call put ratio 1 call to 1.1 puts into quarter results